The fall in deaths from hepatitis C in 2016 – the first in more than a decade – has continued into 2017. This is likely to be the result of increased treatment with new direct acting antiviral (DAA) drugs, with an increase of nearly 50 per cent over the last year, and of nearly 90 per cent when compared to earlier years.

Now that hepatitis C is much easier to treat, Public Health England is pushing to reduce its prevalence. A problem is that a substantial number of the estimated 214,000 people living with hep C infection may be unaware they have the virus.

Despite its debilitating effect on the liver – it can cause severe liver damage and cancer – many with hep C may have no specific symptoms, with some (including tiredness and abdominal pain) easily overlooked.

Around one-third of those with the long-term infection are believed to be aged over 50 years and may have contracted the virus years ago. Injecting drug use continues to be the most important risk factor for infection.

PHE is encouraging people to get tested and has drawn up a list of criteria for anyone who is concerned about whether they should get tested. GP practices, GUM clinics and drug treatment services can provide tests.

Originally Published by Pharmacy Magazine

Recommended

New education standards for pharmacy technicians

The GPhC has launched new standards for the initial education and training of pharmacy technicians

GPhC welcomes positive PSA review

The GPhC has met all of the Professional Standards Authority’s standards for good regulation in 2016/17

Popular

Making habits last a lifetime

Falling activity levels in young people are deeply concerning, say experts, so what can be done to encourage youngsters ...

Raising awareness of pancreatic cancer

Public awareness of pancreatic cancer has been slow to catch up with other forms of the disease. So what is this devasta...

Taking on pancreatic cancer

Pancreatic Cancer Action chief executive Ali Stunt speaks to TM about the work the charity does to raise awareness of t...